<DOC>
	<DOCNO>NCT02104700</DOCNO>
	<brief_summary>The study open-label , pilot study virologically suppress patient compare efficacy , safety tolerability two Antiretroviral regimen strategy : Arm A : `` Immediate switch '' Rilpivirine/Emtricitabine/Tenofovir ( single tablet formulation ( STF ) ) randomization Arm B : `` Delayed switch '' Continue Nevirapine/Lamivudine/other Nucleoside reverse transcriptase inhibitor ( NRTI ) 24 week switch STF Rilpivirine/emtrictabine/tenofovir follow 48 week .</brief_summary>
	<brief_title>Switch From Nevirapine-based Regimen Once Day Rilpivirine/Emtricitabine/Tenofovir</brief_title>
	<detailed_description>The current study design first study compare continue nevirapine-based regimen switch FDC rilpivirine/emtricitabine/tenofovir . Rwanda model country implementation new approach innovative ART strategy excellent National HIV Treatment program place limit experience clinical trial African country clinical experience Rilpivirine treating HIV infect adult .</detailed_description>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Rilpivirine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>HIV1 infection , document licensed ELISA test kit confirm Western blot time prior study entry . A second antibody test method ELISA acceptable alternative confirmatory test previous detectable HIV RNA level HIV RNA level limit quantification viral load assay use incountry within last 12 month Screening HIV RNA level limit quantification define local assay At least twelve month stable firstline antiretroviral therapy consist nevirapine 2 nRTIs approve Rwandan HIV Treatment guideline . ( No prior change ART allow ) Enrolled Rwanda National ART Program incountry transfer within program . Negative TB symptom screen eligible base algorithm outline Laboratory value obtain within 30 day prior study entry : Hemoglobin great 8.0 g/dL Platelet count great 40,000/mm3 AST ( SGOT ) , ALT ( SGPT ) , alkaline phosphatase le 5 X ULN Total bilirubin le 2.5 x ULN Calculated creatinine clearance great 60 mL/min estimate CockcroftGault equation : Ability meet nutritional requirement rilpivirine ; large meal consist least 400 total kcals 117 kcals fat ( 13 gram ) assess screening . For woman reproductive potential , negative serum urine pregnancy test within 4 week initiate study medication negative urine pregnancy test entry visit prior randomization . `` Women reproductive potential '' define woman postmenopausal least 24 consecutive month ( i.e. , menses within precede 24 month ) undergo surgical sterilization ( e.g. , hysterectomy , bilateral oophorectomy , tubal ligation ) . Age great than18 year . Ability willingness subject give inform consent . History ontreatment virologic failure ( define HIV RNA level great 200 copies/mL 6 month antiretroviral therapy ) Any change prior ART . Currently breastfeed . Active tuberculosis . Serious illness require systemic treatment and/or hospitalization candidate either completes therapy clinically stable therapy , opinion site investigator , least 14 day prior study entry . NOTE : Isolated cutaneous Kaposi 's Sarcoma , oral candidiasis , vaginal candidiasis , mucocutaneous herpes simplex , nonserious illness ( judge site investigator ) restriction . Known allergy/sensitivity study drug formulation . Active drug alcohol use dependence , opinion site investigator , would interfere adherence study requirement . Requirement current medication prohibit study treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>HIV</keyword>
</DOC>